Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT NASDAQ:FNCH NASDAQ:ITOS NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$4.22-0.9%$4.74$3.75▼$7.20$8.10M1.1227,239 shs6,771 shsFNCHFinch Therapeutics Group$7.30$7.55$2.00▼$16.10$11.72M1.185,025 shsN/AITOSiTeos Therapeutics$10.15$10.14$6.18▼$11.35$448.73M1.311.57 million shsN/APHARPharming Group$12.97+0.8%$14.11$9.54▼$21.34$916.01M-0.0420,683 shs9,426 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics+6.23%-1.16%-13.94%-5.33%-23.93%FNCHFinch Therapeutics Group0.00%0.00%-2.01%0.00%-43.89%ITOSiTeos Therapeutics0.00%0.00%0.00%0.00%+0.40%PHARPharming Group+1.26%+2.88%+2.14%-20.70%+22.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$4.22-0.9%$4.74$3.75▼$7.20$8.10M1.1227,239 shs6,771 shsFNCHFinch Therapeutics Group$7.30$7.55$2.00▼$16.10$11.72M1.185,025 shsN/AITOSiTeos Therapeutics$10.15$10.14$6.18▼$11.35$448.73M1.311.57 million shsN/APHARPharming Group$12.97+0.8%$14.11$9.54▼$21.34$916.01M-0.0420,683 shs9,426 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics+6.23%-1.16%-13.94%-5.33%-23.93%FNCHFinch Therapeutics Group0.00%0.00%-2.01%0.00%-43.89%ITOSiTeos Therapeutics0.00%0.00%0.00%0.00%+0.40%PHARPharming Group+1.26%+2.88%+2.14%-20.70%+22.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.40Hold$34.67716.26% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AITOSiTeos Therapeutics 2.33Hold$10.755.91% UpsidePHARPharming Group 2.40Hold$38.33195.08% UpsideCurrent Analyst Ratings BreakdownLatest BOLT, FNCH, OXB, PHAR, and ITOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026BOLTBolt Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/28/2026BOLTBolt Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.005/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)4/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/20/2026BOLTBolt Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026PHARPharming Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/10/2026PHARPharming Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$37.003/30/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/24/2026PHARPharming Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$37.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.70M1.06N/AN/A$13.81 per share0.31FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91PHARPharming Group$369.49M2.48$0.21 per share63.37$3.95 per share3.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$33.38M-$16.33N/AN/AN/A-455.15%-100.89%-48.23%8/13/2026 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/AITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%N/APHARPharming Group$2.85M$0.1681.2019.99N/A3.30%4.64%2.55%7/30/2026 (Estimated)Latest BOLT, FNCH, OXB, PHAR, and ITOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026BOLTBolt Biotherapeutics-$2.85-$4.31-$1.46-$4.31$1.50 million$0.03 million5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.983.513.51FNCHFinch Therapeutics GroupN/A3.873.87ITOSiTeos TherapeuticsN/A7.537.53PHARPharming Group0.352.632.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%FNCHFinch Therapeutics Group21.77%ITOSiTeos Therapeutics97.16%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics9.40%FNCHFinch Therapeutics Group44.90%ITOSiTeos Therapeutics14.20%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.74 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataITOSiTeos Therapeutics9044.21 million37.93 millionOptionablePHARPharming Group28070.63 million69.16 millionNot OptionableBOLT, FNCH, OXB, PHAR, and ITOS HeadlinesRecent News About These CompaniesPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Consensus Recommendation of "Hold" from AnalystsJune 24 at 4:17 AM | americanbankingnews.comUS FDA accepts Pharming’s supplemental NDA resubmission for Joenja to treat children aged 4 to 11 years with APDSJune 6, 2026 | pharmabiz.comPPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSJune 5, 2026 | markets.businessinsider.comPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSJune 4, 2026 | globenewswire.comPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkJune 2, 2026 | finance.yahoo.comPharming Group N.V.: Pharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28, 2026 | finanznachrichten.dePharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28, 2026 | manilatimes.netMPharming Group N.V. (PHAR) Shareholder/Analyst Call - SlideshowMay 28, 2026 | seekingalpha.comPharming’s Joenja receives European marketing authorization for the treatment of activated PI3K delta syndromeMay 26, 2026 | pharmabiz.comPEuropean Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionMay 22, 2026 | markets.businessinsider.comPharming Group N.V. Recorded A 21% Miss On Revenue: Analysts Are Revisiting Their ModelsMay 10, 2026 | finance.yahoo.comPharming Group (PHAR) Gets a Buy from Canaccord GenuityMay 9, 2026 | theglobeandmail.comPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026May 7, 2026 | markets.businessinsider.comPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersMay 7, 2026 | markets.businessinsider.comPharming Group N.V. (PHAR) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comPharming Group N.V. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comPharming earnings in focus: Can rare disease growth offset Q1 dip?May 6, 2026 | investing.comPharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 6, 2026 | finance.yahoo.comPharming Group ADR PHGMay 5, 2026 | morningstar.comMHigh Growth Tech Stocks To Watch In May 2026May 5, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMarvell’s Pullback May Be the Setup Bulls Were Waiting ForBy Thomas Hughes | May 29, 2026Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNowBy Thomas Hughes | June 3, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026Eli Lilly Wins Back CVS Health, Reverting Novo's AdvantageBy Leo Miller | June 2, 2026Semtech’s Explosive Rally May Only Be Getting StartedBy Thomas Hughes | May 28, 2026BOLT, FNCH, OXB, PHAR, and ITOS Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$4.22 -0.04 (-0.94%) Closing price 04:00 PM EasternExtended Trading$4.16 -0.06 (-1.42%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Finch Therapeutics Group NASDAQ:FNCH$7.30 0.00 (0.00%) As of 06/23/2026Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.iTeos Therapeutics NASDAQ:ITOSiTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Pharming Group NASDAQ:PHAR$12.97 +0.10 (+0.78%) Closing price 03:58 PM EasternExtended Trading$12.76 -0.22 (-1.66%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
